New insights in antigen processing and epitope selection: Development of novel immunotherapeutic stragies for cancer, autoimmunity and infectious diseases

Journal of Biological Regulators and Homeostatic Agents

Volumn 19, Issue 3-4, 2005, Pages 93-104

  Haque, Azizul ^a   Blum, J S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presenting cells; Antigen processing and presentation; Autoimmunity; Cancer; Epitope selection; Infectious diseases; Lysosomal reductase GILT; MHC class II

Indexed keywords

BACTERIAL VACCINE; CARDIAC MYOSIN; CATHEPSIN B; CATHEPSIN D; CD4 ANTIGEN; COLLAGEN TYPE 2; COLLAGEN TYPE 5; CYTOMEGALOVIRUS VACCINE; EPITOPE; FC RECEPTOR; GLYCOPROTEIN GP 39; HEAT SHOCK PROTEIN 65; HEPATITIS B VACCINE; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; HLA DO ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G; LISTERIOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; RAS PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE; UNINDEXED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL IMMUNITY; BRAIN CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELLULAR IMMUNITY; COLON CANCER; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; ENTERITIS; EPITOPE MAPPING; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFECTION; LUNG GRAFT REJECTION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MICROBIAL IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; RHEUMATOID ARTHRITIS; SKIN SURGERY; TUMOR IMMUNITY; VACCINE PRODUCTION; VIRUS IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; INFECTION; NEOPLASMS; TRANSPLANTATION IMMUNOLOGY;

EID: 33744532405     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T-cells. Proc Natl Acad Sci USA 1982; 79: 175-8.
2. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993; 11: 403-50 (review).
3. Nijman HW, Kleijmeer MJ, Ossevoort, MA et al. Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med 1995; 182: 163-74.
4. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T-cell antigenic determinants. Annu Rev Immunol 1993; 11: 729-66 (review).
5. Blum JS, Ma C, Kovats S. Antigen presenting cells and the selection of immunodominant epitopes. Crit Rev Immunol 1997; 17: 411-7.
6. + responses to viruses: Cell biology, cellular immunology, and mathematical models. Immunity 2004; 21: 149-53.
7. Byersdorfer CA, Dipaolo RJ, Petzold SJ, Unanue ER. Following immunization antigen becomes concentrated in a limited number of APCs including B cells. J Immunol 2004; 173: 6627-34.
8. Ma C, Whiteley PE, Cameron PM, Freed DC, Pressey A, Chen SL, Garni-Wagner B, Fang C, Zaller DM, Wicker LS, Blum JS. Role of APC in the selection of immunodominant T-cell epitopes. J Immunol 1999; 163: 6413-23.
9. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1988; 396: 695.
10. Nakagawa T, Roth W, Wong P, et al. Cathepsin L: Critical role in Ii degradation and CD4 T-cell selection in the thymus. Science 1988; 280: 450.
11. Li P, Haque MA, Blum JS. Role of disulfide bonds in regulating antigen processing and epitope selection. J Immunol 2002; 169: 2444-50.
12. Haque MA, Hawes JW, Blum JS. Cysteinylation of MHC class II ligands: Peptide endocytosis and reduction within APC influences T-cell recognition. J Immunol 2001; 166:4543-51.
13. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T-cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire. J Exp Med 2000; 191: 761-70.
14. Schneider SC, Ohmen J, Fosdick L, et al. Cutting edge: Introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T-cell determinant display. J Immunol 2000; 165: 20-3.
15. Ria F, Gallard A, Gabaglia CR, Guery JC, Sercarz EE, Adorini L. Selection of similar naive T-cell repertoires but induction of distinct T-cell responses by native and modified antigen. J Immunol 2004; 172: 3447-53.
16. Maynard J, Petersson K, Wilson DH, et al. Structure of an autoimmune T-cell receptor complexed with class II peptide-MHC: Insights into MHC bias and antigen specificity. Immunity 2005; 22: 81-92.
17. Nashar TO, Drake JR. The pathway of antigen uptake and processing dictates MHC class II-mediated B cell survival and activation. J Immunol 2005; 174: 1306-16.
18. + T-cells directly from the immunological synapse upon cellular dissociation. J Immunol 2005; 174: 80-9.
19. Haque MA, Li P, Jackson SK, et al. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T-cell recognition of select immunodominant epitopes. J Exp Med 2002; 195: 1267-77.
20. Toes REM, Ossendorp F, Offringa R, Melief CJM. CD4 T-cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-6.
21. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immuno-surveillance and immunotherapy. Nat Immunol 2001; 2: 293-9.
22. Thayer WP, Kraft JR, Tompkins SM, Moore JC 4th, Jensen PE. Assessment of the role of determinant selection in genetic control of the immune response to insulin in H-2b mice. J Immunol 1999; 163: 2549-54.
23. + T lymphocytes from Anaplasma marginale major surface protein 2 (MSP2) vaccinees recognize naturally processed epitopes conserved in MSP3. Infect Immun 2004; 72: 3688-92.
24. + T-cell responses against HCV: Analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. J Viral Hepat 2004; 11: 324-31.
25. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997; 15: 821.
26. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622.
27. Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992; 256: 1817.
28. Toes REM, Ossendorp F, Offringa R, Melief CJM. CD4 T-cells and their role in antitumor immune responses. J Exp Med 1999; 189: 7536.
29. Watts C, Amigorena S. Antigen traffic pathways in dendritic cells. Traffic 2000; 1: 312-7.
30. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997; 94: 6886-91.
31. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med 2004; 200: 1039-49.
32. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988; 85: 3975-9.
33. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimmers and facilitates peptide loading. Cell 1995; 82: 155-65.
34. Liljedahl M, Kuwana T, Fung-Leung WP, et al. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996; 15: 4817-24.
35. Glazier KS, Hake SB, Tobin HM, Chadburn A, Schattner EJ, Denzin LK. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J Exp Med 2002; 195: 1063-9.
36. Lovitch SB, Petzold SJ, Unanue ER. Cutting edge: H-2DM is responsible for the large differences in presentation among peptides selected by I-Ak during antigen processing. J Immunol 203; 171: 2183-6.
37. Chen X, Jensen PE. The expression of HLA-DO (H2-O) in B lymphocytes. Immunol Res 2004; 29: 19-28 (review).
38. Unanue ER. Antigen presenting function of the macrophage. Annu Rev Immunol 1984; 2: 395-428.
39. Pinet V, Malnati, MS, Long EO. Two processing pathways for the MHC class II restricted presentation of exogenous influenza virus antigen. J Immunol 1994; 152: 4852-60.
40. Maric M, Arunachalam B, Phan UT, et al. Defective antigen processing in GILT-free mice. Science 2001; 294: 1361-5.
41. + T-cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183: 1965-71.
42. + T-cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-94.
43. + cytotoxic T-cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999; 189: 871-6.
44. + T-cell help. J Exp Med 1997; 186: 65-70.
45. + T-cells. Forum (Genova) 2000; 10: 256-70.
46. + melanoma. Int Immunol 1993; 5: 1501-8.
47. + T-cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J Immunol 2005; 174: 3344-51.
48. + T-cells. Cancer Res 2000; 60: 4946-52.
49. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-9.
50. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 1995; 55: 2984-7.
51. Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T-cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003; 63: 8481-6.
52. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28: 26-31.
53. Ostrand-Rosenberg S. Tumor immunotherapy: The tumor cell as an antigen-presenting cell. Curr Opinion in Immunol 1994; 6: 722-27.
54. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-64.
55. Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J Immunol 1998; 160: 2099-106.
56. Negroiu G, Dwek RA, Petrescu SM. Folding and maturation of tyrosinase-related protein-1 are regulated by the post-translational formation of disulfide bonds and by N-glycan processing. J Biol Chem 2000; 275: 32200-7.
57. + T-cells. Br J Cancer 2001; 85: 1738-45.
58. Harding CV, Geuze HJ. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. J Immunol 1993; 151: 3998.
59. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005; 52: 1-9 (review).
60. Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002; 21: 5127-34.
61. Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ. High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers 1998; 13: 139-44.
62. Miyake H, Hara I, Eto H. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Anticancer Res 2004; 24: 2573-7.
63. Gondi CS, Lakka SS, Yanamandra N, et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004; 64: 4069-77.
64. Sivaparvathi M, Sawaya R, Chintala SK, Go Y, Gokaslan ZL, Rao JS. Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 1996; 208: 171-4.
65. Hara I, Miyake H, Yamanaka K, Hara S, Kamidono S. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Oncol Rep 2002; 9: 1379-83.
66. Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of T-cell epitopes - a framework for modelling, testing, and applications. Methods 2004; 34: 436-43.
67. Bian H, Hammer J. Discovery of promiscuous HLA-II-restricted T-cell epitopes with TEPITOPE. Methods 2004; 34: 468-75.
68. Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002; 98: 189-98.
69. Sette A, Keogh E, Ishioka G, et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs 2002; 3: 132-9.
70. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin Cancer Biol 2002; 12: 25-31.
71. Todd JA, Acha-Orbea H, Bell JI, et al. Timmerman, McDevitt HO. A molecular basis for MHC class II-associated autoimmunity. Science 1998; 240: 1003-9.
72. Rosloniec EF, Brand DD, Myers LK, et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1 *0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 1998; 160: 2573-8.
73. Fugger L, Rothberg JB, McDevitt GS. Specificity of an HLA-DRB1 *0401-restricted T-cell response to type II collagen. Eur J Immunol 1996; 26: 928-33.
74. Anderson EC, Hansen BE, Jacobsen H, et al. Definition of MHC and T-cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 1998; 95: 7574-9.
75. Warnock MG, Goodacre JA. Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br J Rheumatol 1997; 36: 1144-50.
76. Sonderstrup G, McDevitt HO. Identification of autoantigen epitopes in MHC class II transgenic mice. Immunol Rev 1998; 164: 129-38.
77. Catchpole B, Hamblin AS, Staines NA. Antigen presentation of type II collagen by B cells. Biochem Soc Trans 1997; 25 (Suppl.): S238.
78. Michaelsson E, Holmdahl M, Engstrom A, Burkhardt H, Scheynius A, Holmdahl R. Macrophages, but not dendritic cells, present collagen to T-cells. Eur J Immunol 1995; 25: 2234-41.
79. Walter W, Loos M, Maeurer MJ. H2-M polymorphism in mice susceptible to collagen-induced arthritis involves the peptide binding groove. Immunogenetics 1996; 44: 19-26.
80. Rosloniec EF, Brand DD, Myers LK, et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 1997; 185: 1113-22.
81. Ebert EC, Mehta V, Das KM. Activation antigens on colonic T-cells in inflammatory bowel disease: Effects of IL-10. Clin Exp Immunol 2005; 140: 157-65.
82. Ruemmele FM, Dionne S, Levy E, Seidman EG. Dexamethasone inhibits IFN-gamma-induced MHC class II expression of intestinal epithelial cells independently of the TGF-beta1 regulatory pathway. Aliment Pharmacol Ther 1999; 13: 595-601.
83. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 2003; 102: 429-35.
84. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of auto-reactive myelin proteolipid protein-specific T-cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire. J Exp Med 2000; 191: 761-70.
85. Bischof F, Bins A, Durr M, Zevering Y, Melms A, Kruisbeek AM. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. J Immunol 2004; 173: 600-6.
86. Klehmet J, Shive C, Guardia-Wolff R, et al. T-cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. Clin Immunol 2004; 111: 53-60.
87. Sinha P, Chi HH, Kim HR, et al. Mouse lysozyme-M knockout mice reveal how the self-determinant hierarchy shapes the T-cell repertoire against this circulating self antigen in wild-type mice. J Immunol 2004; 173: 1763-71.
88. Nakagawa TY, WH Brissette, PD Lira, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999; 10: 207-17.
89. Pathak SS, Lich JD, Blum JS. Cutting edge: Editing of recycling class II: Peptide complexes by HLA-DM. J Immunol 2001; 167:632-5.
90. Fallas JL, Tobin HM, Lou O, Guo D, Sant'Angelo DB, Denzin LK. Ectopic expression of HLA-DO in mouse dendritic cells diminishes MHC class II antigen presentation. J Immunol 2004; 173: 1549-60.
91. Lich JD, Jayne JA, Zhou D, Elliott JF, Blum JS. Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. J Immunol 2003; 171: 853-9.
92. Louis-Plence, Kerlan-Candon S, et al. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism. J Immunol 2000; 165: 4861.
93. Pinet V, Combe B, Avinens O, et al. Polymorphisms of the HLA-DMA and DMB genes in rheumatoid arthritis. Arthritis Rheumatol 1998; 41: 946.
94. Toussirot E, Sauvageot C, Chabod J, Ferrand C, Tiberghien P, Wendling D. The association of HLA-DM genes with rheumatoid arthritis in eastern France. Hum Immunol 2000; 61: 303.
95. Singal DP, Ye M. HLA-DM polymorphisms in patients with rheumatoid arthritis. J Rheumatol 1998; 25: 1295.
96. Moxley G, Han J. HLA DMA and DMB show no association with rheumatoid arthritis in US Caucasians. Eur J Immunogenet 2001; 28: 539.
97. Koh LD, Napolitano G, Singer DS, et al. Graves' disease: A host defense mechanism gone awry. Int Rev Immunol 2001; 19: 633.
98. Cucchi-Mouillot P, Lai S, Carcassi C, et al. Implication of HLA-DMA alleles in corsican IDDM. Dis. Markers 1998; 14: 135.
99. Siegmund T, Donner H, Braun J, Usadel KH, Badenhoop K. HLA-DMA and HLA-DMB alleles in German patients with type I diabetes mellitus. Tissue Antigens 1999; 54: 291.
100. Liljedahl M, Winqvist O, Surh C, et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998; 8: 233.
101. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-05.
102. Sherman LA, hattopadhyan S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385-02.
103. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-8.
104. + T-cells leads to prolonged cardiac xenograft survival. Xenotransplantation 2004; 11: 33-42.
105. + T-cells in allorecognition: Lessons from corneal transplantation. J Immunol 2001; 167:1891-9.
106. van den Berg, JW, Hepkema BG, Geertsma A, et al. Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches. Transplantation 2001; 71: 368-73.
107. Duquesnoy RJ, Liu K, Fu F, et al. Evidence for heat shock protein immunity in a rat cardiac allograft model of chronic rejection. Transplantation 1999; 67: 156-64.
108. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000; 69: 1609-17.
109. Liu K, Moliterno RA, Qian J, et al. Role of heat shock proteins in heart transplant rejection. J Heart Lung Transplant 1996; 15: 222-8.
110. Kalluri R, Torre A III, Shield CF, et al. Identification of a3, a4, and a5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation 2000; 69: 679.
111. Yasufuku K, Heidler KM, Woods K, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500.
112. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: Role of type V collagen-specific T-cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169: 1542.
113. high regulatory T-cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171: 1140-7.
114. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: A focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1129-39 (review).
115. + cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68: 8056-63.
116. + T-cells in protection. Cancer Res 2002; 62: 7234-40.
117. + T-cells: Immunodominance hierarchy and preferential infection with HTLV-I. J Immunol 2004; 172: 1735-43.
118. + T-cells but not interleukin-2. Viral Immunol 2005; 18: 162-9.
119. Neild A, Murata T, Roy CR. Processing and major histocompatibility complex class II presentation of Legionella pneumophila antigens by infected macrophages. Infect Immun 2005; 73: 2336-43.
120. Winslow GM, Roberts AD, Blackman MA, Woodland DL. Persistence and turnover of antigen-specific CD4 T-cells during chronic tuberculosis infection in the mouse. J Immunol 2003; 170: 2046-52.
121. + T-cells and toll-like receptors recognize Salmonella antigens expressed in bacterial surface organelles. Infect Immun 2005; 73: 1350-6.
122. + T-cell responses during natural infection with Salmonella typhimurium. J Immunol 2000; 164: 986-93.
123. Mustafa AS, Oftung F, Amoudy HA, et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T-cell lines. Clin Infect Dis 2000; 3 (Suppl.): S201-5.
124. Srinivasan A, Foley J, Ravindran R, McSorley SJ. Low-dose Salmonella infection evades activation of flagellin-specific CD4 T-cells. J Immunol 2004; 173: 4091-9.
125. Tsuji M, Zavala F. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol Immunol 2001; 38: 433-42 (review).
126. Tuo W, Davis WC, Fetterer R, Jenkins M, Boyd PC, Gasbarre LC, Dubey JP. Establishment of Neospora caninum antigen-specific T-cell lines of primarily CD4 T-cells. Parasite Immunol 2004; 26: 243-6.
127. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T-cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 2004; 172: 483-92.
128. + T-cell response during Listeria monocytogenes infection. J Immunol 2002; 168: 6382-7.
129. + T-cells during murine infection with Listeria monocytogenes. J Immunol 1998; 161: 2339-47.
130. Corbin GA, Harty JT. Duration of infection and antigen display have minimal influence on the kinetics of the CD4+ T-cell response to Listeria monocytogenes infection. J Immunol 2004; 173: 5679-87.
131. Bian H, Hammer J. Discovery of promiscuous HLA-II-restricted T-cell epitopes with TEPITOPE. Methods 2004; 34: 468-75.
132. Sung MH, Simon R. Candidate epitope identification using peptide property models: Application to cancer immunotherapy. Methods 2004; 34: 460-7 (review).
133. Elsawa SF, Rodeberg DA, Celis E. T-cell epitope peptide vaccines. Expert Rev Vaccines 2004; 3: 563-75.
134. Waeckerle-Men Y, Gander B, Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005; 109: 35-46.
135. Khanna R, Burrows SR, Suhrbier A. et al. EBV peptide epitope sensitization restores human cytotoxic T-cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J Immunol 1993; 150: 5154-62.
136. Campos-Lima PO, Levitsky V, Imreh MP, Gavioli R, Masucci MG. Epitope-dependent selection of highly restricted or diverse T-cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med 1997; 186: 83-9.
137. Gregory CD, Tursz T, Edwards CF, et al. Identification of a subset of normal B cells with a Burkitt lymphoma (BL)-like phenotype. J Immunol 1987; 139: 313-8.
138. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al. Fields virology, 3rd edition. Philadelphia: Lippin-cott-Raven, 1996; pp. 2397-446.
139. Lenoir GM, Bornkamm GW. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: Proposal for a new scenario. Adv Viral Oncol 1987; 7: 173-206.
140. Khanna R, Burrows SR, Steigerwald-Mullen PM, Moss DJ, Kurilla MG, Cooper L. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing. Int Immunol 1997; 9: 1537-43.
141. Levitskaya J, Coram M, Levitsky V, Imreh S, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-8.
142. Zwaveling S, Ferreira Mota SC, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-8.
143. Steele JC, Roberts S, Rookes SM, Gallimore PH. Detection of CD4(+)- and CD8(+)-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release. J Virol 2002; 76: 6027-36.
144. + T-cells. J Immunol 2001; 166: 5250-7.
145. Li Pira G, Bottone L, Ivaldi F, et al. Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool. Hum Immunol 2004; 65: 537-43.
146. Penna A, Artini M, Cavalli A, et al. Long-lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
147. Mizukoshi E, Sidney J, Livingston B, et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004; 173: 5863-71.
148. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T-cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
149. Mertz AK, Wu P, Sturniolo T, et al. Multispecific CD4+ T-cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: Overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J Immunol 2000; 164: 1529-37.
150. Neild A, Murata T, Roy CR. Processing and major histocompatibility complex class II presentation of Legionella pneumophila antigens by infected macrophages. Infect Immun 2005; 73: 2336-43.
151. + T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37: 577-89.
152. Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004; 64: 5830-8.